Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Open-label, Multicenter, Safety and Efficacy Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B

NCT01496274 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT01496274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01496274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Open-label, Multicenter, Safety and Efficacy Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B
Lead sponsor
CSL Behring
Phase
Phase 2/3
Overall status
Completed
Start date
February 29, 2012
Completion date
Not reported
Enrollment
63 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia b